Peng Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peng Xia has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Xi Chen
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
21 shared publications - Jie Liu
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, People’s Republic of China
20 shared publications - Weijie Ma
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
20 shared publications - Wenzhi He
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
20 shared publications - Yingyi Liu
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, People’s Republic of China
20 shared publications - Dongzhi Cairang
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
19 shared publications
Latest Publications
- Open Access
A U1–U3 snRNA–snoRNA interaction couples SF3B1 mutation to chromatin-state rewiring and genome instability
Mutations in spliceosome factors such as SF3B1 are recurrent across human diseases, including myelodysplastic syndromes and leukemia 1–4 , yet splicing defects alone do not fully explain the widespread chromatin alterations and genome instability in mutant cells 5 . Here, by comprehensively mapping snRNA-directed RNA–RNA interactions, we identify two previously unrecognized interaction motifs in U1 snRNA beyond canonical 5′ splice-site pairing 6,7 . These motifs enable U1 RNA to i) bind intronic and other chromatin-associated RNA (caRNA) regions outside of splice sites, and ii) base pair specifically with snoRNA. We uncover a U1–U3 snRNA–snoRNA interaction that recruits the H3K36 methyltransferase SETD2 to caRNA, promoting gene-body H3K36me3 and antagonizing H3K27me3 to modulate chromatin accessibility. The snRNA–snoRNA interface is essential for this previously unrecognized layer of chromatin and transcriptional regulation mediated through SETD2. SF3B1 mutation enhances U1–U3 binding and increases the association of the U1–U3 complex with caRNA, driving chromatin-accessibility remolding, R-loop formation, DNA damage, and copy-number abnormalities that promote tumorigenesis. A U1-specific 2′-O-methoxyethyl antisense oligonucleotide that selectively blocks U1–U3 pairing suppresses these genomic abnormalities, reduces leukemic infiltration, and prolongs survival in xenograft and patient-derived models, establishing pathological snRNA–snoRNA rewiring as a critical driver of SF3B1-mutant leukemogenesis.
Open AccessA U1–U3 snRNA–snoRNA interaction couples SF3B1 mutation to chromatin-state rewiring and genome instability
Mutations in spliceosome factors such as SF3B1 are recurrent across human diseases, including myelodysplastic syndromes and leukemia 1–4 , yet splicing defects alone do not fully explain the widespread chromatin alterations and genome instability in mutant cells 5 . Here, by comprehensively mapping snRNA-directed RNA–RNA interactions, we identify two previously unrecognized interaction motifs in U1 snRNA beyond canonical 5′ splice-site pairing 6,7 . These motifs enable U1 RNA to i) bind intronic and other chromatin-associated RNA (caRNA) regions outside of splice sites, and ii) base pair specifically with snoRNA. We uncover a U1–U3 snRNA–snoRNA interaction that recruits the H3K36 methyltransferase SETD2 to caRNA, promoting gene-body H3K36me3 and antagonizing H3K27me3 to modulate chromatin accessibility. The snRNA–snoRNA interface is essential for this previously unrecognized layer of chromatin and transcriptional regulation mediated through SETD2. SF3B1 mutation enhances U1–U3 binding and increases the association of the U1–U3 complex with caRNA, driving chromatin-accessibility remolding, R-loop formation, DNA damage, and copy-number abnormalities that promote tumorigenesis. A U1-specific 2′-O-methoxyethyl antisense oligonucleotide that selectively blocks U1–U3 pairing suppresses these genomic abnormalities, reduces leukemic infiltration, and prolongs survival in xenograft and patient-derived models, establishing pathological snRNA–snoRNA rewiring as a critical driver of SF3B1-mutant leukemogenesis.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Transcriptomic and functional effects of DDC and SLC6A4 overexpression in prostate cancer cells.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Transcriptomic and functional effects of DDC and SLC6A4 overexpression in prostate cancer cells.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Supplementary Table Oligonucleotides
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Supplementary Table Oligonucleotides
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant subtype of prostate cancer characterized by lineage plasticity. Although metabolic and signaling molecules are increasingly recognized as modulators of tumor progression, their role in cell fate transition remains unclear. NE (neuroendocrine) tumors produce and accumulate serotonin, a neurotransmitter that regulates diverse physiologic processes. In this study, we identify a tumor-intrinsic serotonin axis as a key driver of NEPC lineage commitment and progression. NEPC endogenously synthesizes serotonin via aromatic L-amino acid decarboxylase (AADC; encoded by DDC) and reuptakes it through the transporter SLC6A4. Mechanistically, high levels of intracellular serotonin promote histone serotonylation at H3K4me3Q5, reconfiguring the H3K4me3 chromatin landscape and downstream gene expression, which drives NE differentiation and is associated with suppressed androgen receptor signaling. Pharmacologic inhibition of serotonin synthesis using the FDA-approved DDC inhibitor carbidopa significantly impairs tumor growth and prolongs survival in both genetically engineered and patient-derived xenograft models, highlighting histone serotonylation as a druggable vulnerability in NEPC.Significance:Collectively, our findings uncover an epigenetically embedded, serotonin-driven lineage program in NEPC, coupling tumor-intrinsic serotonin metabolism with tumor cell fate control, and identify histone serotonylation as a tractable therapeutic vulnerability in lineage-plastic prostate cancer.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant subtype of prostate cancer characterized by lineage plasticity. Although metabolic and signaling molecules are increasingly recognized as modulators of tumor progression, their role in cell fate transition remains unclear. NE (neuroendocrine) tumors produce and accumulate serotonin, a neurotransmitter that regulates diverse physiologic processes. In this study, we identify a tumor-intrinsic serotonin axis as a key driver of NEPC lineage commitment and progression. NEPC endogenously synthesizes serotonin via aromatic L-amino acid decarboxylase (AADC; encoded by DDC) and reuptakes it through the transporter SLC6A4. Mechanistically, high levels of intracellular serotonin promote histone serotonylation at H3K4me3Q5, reconfiguring the H3K4me3 chromatin landscape and downstream gene expression, which drives NE differentiation and is associated with suppressed androgen receptor signaling. Pharmacologic inhibition of serotonin synthesis using the FDA-approved DDC inhibitor carbidopa significantly impairs tumor growth and prolongs survival in both genetically engineered and patient-derived xenograft models, highlighting histone serotonylation as a druggable vulnerability in NEPC.Significance:Collectively, our findings uncover an epigenetically embedded, serotonin-driven lineage program in NEPC, coupling tumor-intrinsic serotonin metabolism with tumor cell fate control, and identify histone serotonylation as a tractable therapeutic vulnerability in lineage-plastic prostate cancer.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Serotonin-associated genes and pathways are enriched in NEPC.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Serotonin-associated genes and pathways are enriched in NEPC.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
AR blockade induces DDC upregulation and serotonin-dependent neuroendocrine lineage reprogramming.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
AR blockade induces DDC upregulation and serotonin-dependent neuroendocrine lineage reprogramming.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Supplementary Table. List of antibodies and small molecules used in this project
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Supplementary Table. List of antibodies and small molecules used in this project
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Transcriptomic stratification of prostate cancer patient cohorts reveals serotonin-axis activation in NE⁺ tumors.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Transcriptomic stratification of prostate cancer patient cohorts reveals serotonin-axis activation in NE⁺ tumors.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Supplementary Table S3. 5-HT pathway drugs in high-throughput drug screening
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Supplementary Table S3. 5-HT pathway drugs in high-throughput drug screening
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Serotonylation-dependent chromatin remodeling coordinates SOX9, EZH2, and ASCL1 regulatory networks in NEPC.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming
Serotonylation-dependent chromatin remodeling coordinates SOX9, EZH2, and ASCL1 regulatory networks in NEPC.